Curi Bio is a biotechnology company focused on developing human-relevant platforms for drug discovery and development. The company integrates advanced 3D tissue models of disease, biosystems for clinically relevant functional analyses, and AI-enabled data analytics to provide predictive insights into drug safety, efficacy, and potency. Its offerings include engineered cardiac, skeletal muscle, and neuromuscular tissue models derived from human iPSCs, as well as custom disease model development, assay development, and therapeutic potency testing. Curi Bio’s integrated preclinical platform supports biopharmaceutical researchers in generating functional human data to bridge the gap between preclinical R&D and clinical outcomes. The company serves global pharmaceutical and biotechnology companies seeking to accelerate the discovery and development of safer, more effective medicines.